5M FLOAT = LGV*
NeuroSense surges on FDA nod to study ALS candidate in healthy subjects
Mar. 21, 2022 9:03 AM ETNeuroSense Therapeutics Ltd. (NRSN)
By: Dulan Lokuwithana, SA News Editor
Israel-based, clinical-stage biotech, NeuroSense Therapeutics (NASDAQ:NRSN) has added ~32% in the pre-market Monday after announcing that the U.S. Food and Drug Administration (FDA) greenlighted a pharmacokinetic study for its lead asset, PrimeC in healthy adult subjects.
An oral combination of FDA-approved drugs, ciprofloxacin, and celecoxib, PrimeC is designed to target amyotrophic lateral sclerosis (ALS).
With its Investigational New Drug (IND) application, NeuroSense (NRSN) has sought the FDA nod to run a pharmacokinetic study to evaluate the effects of food on the bioavailability of PrimeC as opposed to the bioavailability of co-administered ciprofloxacin and celecoxib. The Phase 1 study is set to involve 12 healthy adults in the US.
NeuroSense (NRSN) has already completed a successful Phase IIa trial for the candidate, and a Phase IIb global study is expected to start in Q2 2022.
Yep!! As I noted, pure 'SUCKERS BATE' right out of the starting gate today!!
And all because the SEC, OTC, & FBI finally have-assed 'CLEANED-UP' the OTC Cirus!
And here's why: NRSN is a classic 'Suckers Bate' play for the REST of this day, Homeboys!!! And all behind a POTENTIAL "Lou Gehrig's Disease" treatment???!!! Are you fluckin' KIDDING me???!!! A disease that afflicts ONLY 5,000 peeps per year in the USA --- but NRSN Company is gonna SOAR in price forever now, right????? This PRICE per share ain't gonna last another 10-minutes!!! Are you feelin' LUCKY????!!!!!
Should spike after Thursday presentation.
Most of the time I take Israel-based pharmaceutical companies seriously and was wondering if this company is one that meets the "seriously" criteria, so to speak.
Do you perhaps support this view or at least see potential here?
Will be pleased to heat from you.
NeuroSense Therapeutics started at buy with $7 stock price target at Maxim Group
7:32 am ET January 7, 2022 (MarketWatch)
NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease.